Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study

Key Points

• This study evaluates osimertinib as a second-line treatment option for patients with non-small cell lung cancer after TKI therapy with unknown EGFR mutation status.
• Retrospective analysis of patients with non-small cell lung cancer
• Assessment of osimertinib efficacy following first- and second-generation TKI therapy
• Examination of response rates and treatment duration without rebiopsy for T790M status
• The response rate to osimertinib was 42.7%.
• Median duration of treatment was 5.6 months.
• Outcomes reported for osimertinib were consistent with historical outcomes for second-line chemotherapy.